Jonathan Pachter

Jonathan Pachter boasts a remarkable 25 years of industrial drug discovery expertise in both Large Pharma and Biotech settings.

He has demonstrated proficiency in small molecule and monoclonal antibody discovery, with a focus on translational research.

Noteworthy accomplishments include the delivery of IND-track candidates, particularly in the areas of Cancer and Anti-Inflammatory therapeutics.

Jonathan has played a pivotal role in the discovery of 8 agents that advanced to development, with 4 agents entering phase I - III clinical trials.

His contributions cover in-licensing and translational research, notably shepherding 5 small molecules through clinical development, such as at Verastem.

He has been instrumental in the regulatory approval processes of prominent drugs like Temodar® and has led translational research endeavors for Tarceva®.

With a reputation for defining, building, and communicating company platforms, Jonathan spearheaded the Immuno-Oncology and Cancer Stem Cell platforms at Verastem and the EMT platform at OSI.

He excels in departmental leadership, offering guidance and mentorship to Project Team Leaders.

His leadership extends to building and managing multi-site teams across global corporations and establishing a portfolio of collaborations within academic and inter-company contexts.

In addition to his drug discovery acumen, Jonathan holds 20 years of experience in in-licensing, conducting due diligence evaluations, and business development activities.

He is adept at engaging with various stakeholders including analysts, investors, journalists, Board of Directors, and Scientific Advisory Boards.

Jonathan's expertise lies in devising patient/indication/combination selection strategies, as well as developing PD markers for clinical advancement.

His scientific proficiency spans across diverse domains including Immuno-Oncology, protein kinases, enzymatic targets, GPCRs, hormonal regulation, signal transduction, cell biology, and in vivo models.